An illustrative photo of DNA. Courtesy of GeneG
August 3, 2017 | Israeli bio-pharmaceutical company Eloxx has raised $8 million in a Series C funding round led by LPS, a leading healthcare investor. Other investors such as Pontifax VC, Catalyst, KIP, DSC Funds, Dr. Phil Frost, OPKO Health Inc., and private investors also participated. This brings the company’s total equity to $38 million. The Herzliya company develops treatments for patients with rare genetic diseases triggered by mutations like Cystic Fibrosis and Cystinosis. Founded in 2013 by Dr. Silvia Noiman, Eloxx recently merged with Sevion Therapeutics and became a Sevion subsidiary. Sevion will use the name Eloxx and attempt to list its shares on Nasdaq.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023

Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023

Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023

ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments